Oragenics Issues Letter to Shareholders
Investor Relations
Latest Financial Results
Q1 2022
Quarterly Results
Ended Mar 31, 2022
Stock Information
Symbol
NYSE American: OGEN
Price
Change
Day Range
52 Wk Range
Company Overview
Oragenics, Inc. is a development-stage company dedicated to fighting infectious diseases including coronaviruses and multidrug-resistant organisms. Its lead product is Terra CoV-2, an intranasal vaccine candidate to prevent COVID-19 and variants of the SARS-CoV-2 virus. The Terra CoV-2 program leverages coronavirus spike protein research licensed from the NIH and the NRC with a focus on reducing viral transmission and offering a more patient-friendly intranasal administration. Its lantibiotics program features a novel class of antibiotics against bacteria that have developed resistance to commercial antibiotics.
Contact Information
Investor Relations
LHA Investor Relations
Tirth T. Patel
Vice President
T: 212.201.6614
tpatel@lhai.com
Transfer Agent
Continental Stock Transfer and Trust Company
17 Battery Place
New York, NY 10004
T: 212-509-4000